期刊
CURRENT OPINION IN IMMUNOLOGY
卷 42, 期 -, 页码 16-24出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.05.004
关键词
-
类别
资金
- MRC
- NIHR Biomedical Research Centre Programme
- National Institute for Health Research Clinical Research Network
- Barrie Trust
- MRC [MC_UU_12010/5] Funding Source: UKRI
- Medical Research Council [MC_UU_12010/5] Funding Source: researchfish
IL-33 is the most recent addition to the IL-1 cytokine family, identified in 2005 as the ligand of T1/ST2 and inducer of type-2 immune responses. IL-33 has been implicated in a wide range of disease settings, in anti-inflammatory responses and homeostasis, and thus signalling must be strictly regulated. Altered gene expression, post-translational modification, decoy receptor, and receptor signalling are all modulatory mechanisms used to control the IL-33 pathway. Understanding both the genetic and post-translational factors influencing IL-33 activity will be critical for provision of safe effective treatment of type-2 disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据